Related Experiment Videos
Matrix metalloproteinases: pathways of induction by bioactive molecules
Toshihiro Tsuruda1, Lisa C Costello-Boerrigter, John C Burnett
1Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Heart Failure Reviews
|January 24, 2004
Summary
Bioactive molecules regulate extracellular matrix turnover, impacting heart failure. Targeting these molecules offers therapeutic strategies to reduce adverse ventricular remodeling.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Biochemistry
Background:
- Extracellular matrix (ECM) regulation is crucial for mitigating adverse ventricular remodeling in heart failure.
- Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) play key roles in ECM remodeling during heart failure progression.
Purpose of the Study:
- To investigate the role of bioactive molecules in regulating ECM turnover.
- To explore the potential of targeting bioactive molecules for heart failure therapy.
Main Methods:
- Analysis of MMP/TIMP activity in relation to bioactive molecule levels.
- Evaluation of collagen synthesis and degradation pathways.
- Assessment of therapeutic interventions targeting pro-fibrotic and anti-fibrotic signaling.
Main Results:
- Bioactive molecules directly influence myocardial collagen synthesis and degradation.
- Pro-fibrotic factors (norepinephrine, angiotensin II, endothelin-1) stimulate fibrosis.
- Antagonism of pro-fibrotic molecules improved cardiac function and reverse remodeling.
- Natriuretic peptides and nitric oxide exhibit anti-fibrotic effects via cGMP signaling.
- Cytokines and bioactive molecules synergistically modulate MMP activity.
Conclusions:
- Bioactive molecules are critical regulators of ECM turnover in heart failure.
- Pharmacological targeting of bioactive molecules presents a promising therapeutic avenue for heart failure treatment.
- Modulating MMP/TIMP activity is a key mechanism in achieving reverse remodeling.